Table 4.
Top Canonical Pathways | p-Value | Overlap | Ratio |
Sperm Motility | 1.06 × 10−5 | 3.6% | 8/225 |
Nitric Oxide Signaling in the Cardiovascular System | 1.65 × 10−5 | 5.2% | 6/115 |
Cellular Effects of Sildenafil (Viagra) | 3.73 × 10−4 | 3.8% | 5/131 |
Axonal Guidance signaling | 2.39 × 10−3 | 1.6% | 8/501 |
IL-15 Production | 2.49 × 10−3 | 3.3% | 4/121 |
Top Upstream Regulators | p-value of overlap | Predicted activation | |
TGFB1 | 3.63 × 10−8 | Activated | |
ROCK2 | 5.12 × 10−7 | - | |
PPARGC1A | 2.24 × 10−6 | - | |
IGFBP2 | 2.69 × 10−6 | Activated | |
KLF4 | 2.73 × 10−6 | Activated | |
Top Molecular and Cellular Functions | p-value | # Genes | |
Cellular Movement | 3.87 × 10−3–9.67 × 10−7 | 39 | |
Cellular Assembly and Organization | 3.30 × 10−3–1.39 × 10−6 | 31 | |
Cellular Function and Maintenance | 3.30 × 10−3–1.39 × 10−6 | 37 | |
Cellular Development | 3.49 × 10−3–8.20 × 10−6 | 42 | |
Cellular Growth and Proliferation | 3.49 × 10−3–8.20 × 10−6 | 33 | |
Physiological System Development and Function | p-value range | # Genes | |
Organismal Development | 3.80 × 10−3–2.28 × 10−7 | 58 | |
Tissue Development and Function | 3.80 × 10−3–1.12 × 10−6 | 47 | |
Respiratory System Development and Function | 6.94 × 10−3–1.85 × 10−6 | 15 | |
Cardiovascular System Development and Function | 3.80 × 10−3–6.23 × 10−6 | 43 | |
Tissue Development | 3.80 × 10−3–6.50 × 10−6 | 33 | |
Top Up-regulated genes | Low vs High lysine | Top Down-regulated genes | Low vs High lysine |
ANO6 | 8.426 | LRRC75B | −7.410 |
ADAMTS2 | 8.185 | ANKRD22 | −7.359 |
SEMA3C | 7.651 | ANGPTL4 | −3.017 |
PRKAR2B | 7.599 | ADAMTS20 | −2.87 |
UPK1B | 7.567 | MAGI2 | −2.43 |
CYBRD1 | 7.489 | KIF21A | −2.33 |
ADTRP | 7.370 | CCDC77 | −2.30 |
ROR2 | 7.319 | ABCC4 | −2.20 |
ITGB6 | 7.267 | CACNA1C | −2.01 |
PDE1C | 7.267 | LRP6 | −1.56 |
Ingenuity pathway analysis (IPA) was used for functional analysis of DEGs found in the low lysine vs. high lysine contrast. The top 10 upregulated and downregulated DEGs are presented, along with their respective log2 ratio of treatment conditions.